XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net sales $ 680,800 $ 747,049 $ 2,071,961 $ 2,189,776
Cost of goods sold 307,008 309,614 898,628 950,116
Gross profit 373,792 437,435 1,173,333 1,239,660
Selling, general and administrative expense 211,047 216,150 617,371 655,428
Research and Development Expense 69,949 64,481 199,526 201,784
Segment profit (loss) 92,796 156,804 356,436 382,448
Interest expense 11,663 426 26,431 1,187
Foreign exchange (gains) losses, net 4,364 2,232 3,133 542
Marketable Securities, Unrealized (Gain) Loss 288,999 (4,868,659) 6,172,306 (7,078,753)
Other Nonoperating Income (Expense) 3,062 (579) 42,369 16,732
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (209,168) 5,022,226 (5,803,065) 7,476,204
(Provision) benefit for income taxes 44,936 (1,094,193) 1,342,036 (1,656,643)
Net income attributable to Bio-Rad $ (164,232) $ 3,928,033 $ (4,461,029) $ 5,819,561
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ (5.52) $ 131.75 $ (149.60) $ 195.29
Weighted average common shares - basic 29,733 29,814 29,819 29,800
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ (5.52) $ 129.96 $ (149.60) $ 192.76
Weighted average common shares - diluted 29,733 30,224 29,819 30,190